女性性機能障害治療の市場規模、シェア、成長分析：薬剤別、疾患別、投与経路別、流通チャネル別、地域別 - 産業予測 2025～2032年

女性性機能障害治療の世界市場規模は、2023年に4億8,050万米ドルと評価され、2024年の5億4,297万米ドルから2032年には14億4,344万米ドルに成長し、予測期間（2025～2032年）のCAGRは13％で成長する見通しです。

女性の性機能障害（FSD）治療市場は、性の健康に対する意識の高まりと、医療介入を求める女性の意欲の高まりによって、大きな成長を遂げています。社会規範が進化し、女性のセクシュアリティをめぐる議論がよりオープンになるにつれて、こうした問題を取り巻く偏見が薄れ、革新的な治療への道が開かれます。市場促進要因としては、女性の高齢化、特にホルモン関連機能障害に直面している閉経後の女性が挙げられます。多様なホルモン療法や非ホルモン療法が利用可能になり、個別化医療や遠隔医療の進歩と相まって、治療へのアクセスが向上しています。このような前向きな動向にもかかわらず、文化的タブー、薬物承認の制限、規制上のハードルといった課題は依然として残っています。しかし、進行中の臨床研究や、教育と技術革新への関心の高まりは、将来の市場拡大の可能性を強く示唆しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 臨床試験
• パイプライン分析

女性性機能障害治療市場規模：薬剤別

• 市場概要
• フリバンセリン
• ブレメラノタイド
• オスペミフェン
• エストロゲン療法
• その他

女性性機能障害治療市場規模：疾患別

• 市場概要
• 性欲減退障害（HSDD）
• 性交痛
• その他

女性性機能障害治療市場規模：投与経路別

• 市場概要
• オーラル
• 非経口
• 局所

女性性機能障害治療市場規模：流通チャネル別

• 市場概要
• 病院薬局
• ドラッグストアと薬局
• オンライン薬局

女性性機能障害治療市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Millendo Therapeutics（Tempest Therapeutics）
• AbbVie
• TherapeuticsMD
• Sorrento Therapeutics
• Palatin Technologies
• Eureka Therapeutics
• HRA Pharma
• NantKwest
• Bristol-Myers Squibb
• Pfizer
• Allergen
• Bayer
• Neurotrope
• AMAG Pharmaceuticals
• Sprout Pharmaceuticals, Inc.（U.S.）
• Mayne Pharma Group Limited（Australia）
• Millicent Pharma Ltd.（Endoceutics, Inc.）（Ireland）
• Duchesnay Pharmaceutical Group Inc.（Canada）
• Freya Pharma Solutions B.V.（Netherlands）
• Acerus Pharmaceuticals Corporation（Canada）

結論と提言

Global Female Sexual Dysfunction Treatment Market size was valued at USD 480.5 Million in 2023 and is poised to grow from USD 542.97 Million in 2024 to USD 1443.44 Million by 2032, growing at a CAGR of 13% during the forecast period (2025-2032).

The female sexual dysfunction (FSD) treatment market is witnessing significant growth, driven by rising awareness of sexual health and an increased willingness among women to seek medical interventions. As societal norms evolve and discussions around female sexuality become more open, stigma surrounding these issues diminishes, paving the way for innovative treatments. Key market drivers include an aging female population, particularly postmenopausal women facing hormonal-related dysfunction. The availability of diverse hormonal and non-hormonal therapies, coupled with advancements in personalized medicine and telemedicine, enhances access to treatment. Despite these positive trends, challenges like cultural taboos, limited medication approvals, and regulatory hurdles persist. However, ongoing clinical research and a growing focus on education and innovation signal strong potential for future market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Female Sexual Dysfunction Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Female Sexual Dysfunction Treatment Market Segments Analysis

The global Female Sexual Dysfunction (FSD) Treatment market is segmented by drug, disorder, route of administration, and distribution channel. Key drugs include Flibanserin, Bremelanotide, Ospemifene, and Estrogen Therapy, with hormonal and non-hormonal therapies gaining traction. Major disorders treated are Hypoactive Sexual Desire Disorder (HSDD) and Dyspareunia. Oral administration leads due to convenience, while topical and parenteral options are growing. Distribution channels include hospital, retail, and online pharmacies, with online platforms expanding rapidly. North America dominates the market, while Asia Pacific shows strong growth driven by rising awareness, digital health adoption, and improved access to treatments across emerging healthcare systems.

Driver of the Global Female Sexual Dysfunction Treatment Market

The demand for treatment of Female Sexual Dysfunction (FSD) is being significantly driven by the growing awareness surrounding women's health issues and the increasing incidence of related conditions, such as symptoms associated with menopause, hormonal imbalances, and dysfunctions stemming from stress. The impact of contemporary lifestyles has led to heightened physical and mental health challenges, prompting healthcare systems and providers to incorporate FSD treatments into comprehensive wellness and preventive care strategies. This trend is especially prominent in areas like corporate wellness, reproductive health, and gynecology, where prioritizing sexual health is recognized as essential for enhancing overall quality of life and ensuring long-term well-being.

Restraints in the Global Female Sexual Dysfunction Treatment Market

The Global Female Sexual Dysfunction (FSD) Treatment market faces notable challenges due to high costs associated with specialist consultations, diagnostic tests, and prescribed medications, many of which insurance plans do not cover. This financial burden is especially pronounced for hormonal therapies, branded medications, and long-term treatment options, creating significant obstacles for patients, particularly in low- and middle-income areas. These cost-related issues can dramatically restrict access to necessary care, discouraging many women from pursuing treatment, which ultimately hinders broader acceptance and growth within the market. Addressing these financial barriers is crucial for improving access to FSD therapies.

Market Trends of the Global Female Sexual Dysfunction Treatment Market

The Global Female Sexual Dysfunction (FSD) Treatment market is witnessing a notable trend towards the integration of telehealth and digital therapeutics. This shift addresses the growing demand for discreet, convenient access to consultations, therapies, and prescriptions, thus overcoming geographic limitations and societal stigma often associated with sexual health issues. The appeal of virtual care aligns with patient expectations for privacy and flexibility, enabling continuous monitoring of treatment progress and personalized adjustments in real-time. As healthcare technology advances, it is anticipated that this trend will further enhance patient engagement and satisfaction, ultimately driving the growth of the FSD treatment market globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Clinical Trial
• Pipeline Analysis

Global Female Sexual Dysfunction Treatment Market Size by Drug & CAGR (2025-2032)

• Market Overview
• Flibanserin
• Bremelanotide
• Ospemifene
• Estrogen Therapy
• Others

Global Female Sexual Dysfunction Treatment Market Size by Disorder & CAGR (2025-2032)

• Market Overview
• Hypoactive Sexual Desire Disorder (HSDD)
• Dyspareunia
• Others

Global Female Sexual Dysfunction Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Topical

Global Female Sexual Dysfunction Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Female Sexual Dysfunction Treatment Market Size & CAGR (2025-2032)

• North America (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • US
  • Canada
• Europe (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Millendo Therapeutics (Tempest Therapeutics)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TherapeuticsMD
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Palatin Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eureka Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HRA Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantKwest
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotrope
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AMAG Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sprout Pharmaceuticals, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Millicent Pharma Ltd. (Endoceutics, Inc.) (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Duchesnay Pharmaceutical Group Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freya Pharma Solutions B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acerus Pharmaceuticals Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations